Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2025)

Neurocrine Biosciences' Inventory Average history spans 9 years, with the latest figure at $69.1 million for Q4 2025.

  • For Q4 2025, Inventory Average rose 34.01% year-over-year to $69.1 million; the TTM value through Dec 2025 reached $69.1 million, up 34.01%, while the annual FY2025 figure was $63.2 million, 32.08% up from the prior year.
  • Inventory Average reached $69.1 million in Q4 2025 per NBIX's latest filing, up from $63.1 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $69.1 million in Q4 2025 to a low of $26.9 million in Q3 2021.
  • Average Inventory Average over 5 years is $39.7 million, with a median of $33.9 million recorded in 2023.
  • Peak YoY movement for Inventory Average: decreased 8.75% in 2023, then soared 54.3% in 2025.
  • A 5-year view of Inventory Average shows it stood at $28.0 million in 2021, then increased by 28.75% to $36.0 million in 2022, then fell by 6.93% to $33.6 million in 2023, then soared by 53.8% to $51.6 million in 2024, then surged by 34.01% to $69.1 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Inventory Average are $69.1 million (Q4 2025), $63.1 million (Q3 2025), and $58.0 million (Q2 2025).